GALT earnings analysis
What we found in GALT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing does not provide reported revenue, margins, current-quarter EPS, cash flow, or segment results, so operating trends versus the prior quarter or prior year cannot be assessed. The key balance-sheet development was the July 31, 2026 conversion of approximately $105.8 million of principal and accrued interest into 34,376,167 shares, while a $10.0 million facility remained undrawn and available. The transaction materially reduced debt but increased dilution and shareholder-control risks, and the company continues to report 1 material weakness in internal controls as of June 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Eliminated $105.8M of debt and interest
- The July 31, 2026 debt conversion eliminated $91.0 million of principal and approximately $14.8 million of accrued interest, or approximately $105.8 million in total liabilities.
- $10.0M credit facility remains available
- The December 2025 supplemental line remains outstanding, undrawn, and available, providing access to a $10.0 million credit facility.
- Debt converted without cash repayment
- The conversion issued 34,376,167 common shares at a blended average conversion price of approximately $3.07 per share, reducing near-term debt obligations without a cash repayment.
- Post-conversion capital structure disclosed
- Following the transaction, approximately 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material shareholder dilution
- The issuance of 34,376,167 shares increased the share count to approximately 100,849,644 common shares, creating material dilution for existing holders.
- Concentrated shareholder control
- Richard E. Uihlein beneficially owns approximately 44.3% of actual voting power and approximately 49.3% including shares issuable upon warrant exercise, creating significant concentration of control.
- Material internal-control weakness persists
- Management concluded disclosure controls were not effective as of June 30, 2026 because of 1 material weakness involving valuation controls for derivative liabilities tied to contingent interest on convertible notes; the weakness creates a reasonable possibility of a material misstatement not being detected timely.
- Potential resale registration overhang
- The 34,376,167 shares issued in the conversion are unregistered and subject to resale restrictions, but the company must file a resale registration statement within 180 days after receiving a registration request notice.
- Limited remaining funding capacity
- The filing refers investors to the risk factors in the 2025 Form 10-K and does not identify additional risk-factor changes; the company nevertheless continues to face funding risk despite only $10.0 million remaining available under the undrawn facility.
What they said about what is next.
No quantitative revenue, EPS, operating, or cash-flow guidance was provided in the filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Galectin Therapeutics (GALT) reported negative earnings with no revenue and an EPS of -0.08 for Q4 2026, reflecting a narrowing loss compared to -0.12 the previous quarter. Management highlighted a significant decrease…
- 10-K · March 31, 2026
- Galectin Therapeutics (GALT) is a clinical-stage biopharma focused on its galectin-3 inhibitor belapectin for prevention of esophageal varices in MASH cirrhosis; the company reported mixed NAVIGATE trial results…
- 10-Q · November 14, 2025
- Galectin Therapeutics reported a Q3 net loss of $8,184,000 (EPS $(0.13)), an improvement versus Q3 2024 net loss of $11,220,000 (EPS $(0.18)), driven by sharply lower operating expenses. However, liquidity and…
- 10-Q · May 15, 2025
- Galectin reported Q1 2025 net loss per share of $(0.15), an improvement from $(0.19) in Q1 2024, driven by lower operating expenses (total operating expenses $7,897k vs $9,648k). However, cash declined to $7,431k at…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GALT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever